Kevin Haas - Myriad Genetics Chief Officer
| MYGN Stock | USD 15.71 0.22 1.42% |
Insider
Kevin Haas is Chief Officer of Myriad Genetics
| Age | 38 |
| Address | 322 North 2200 West, Salt Lake City, UT, United States, 84116 |
| Phone | 801 584 3600 |
| Web | https://www.myriad.com |
Myriad Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.1. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 25th of November 2024, Non Currrent Assets Other is likely to grow to about 16.2 M, while Total Assets are likely to drop about 670.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| James Loerop | Aclaris Therapeutics | 59 | |
| Abraham Esq | Caredx Inc | 51 | |
| Douglas Jones | Neogen | 54 | |
| Everett Cunningham | EXACT Sciences | 58 | |
| Vic Parker | EXACT Sciences | N/A | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| John Abbott | Castle Biosciences | N/A | |
| Eric Evans | Natera Inc | N/A | |
| Michael Snyder | Personalis | N/A | |
| Kevin Pegels | Illumina | 56 | |
| Ian Anderson | Aclaris Therapeutics | N/A | |
| Sally Turner | Sotera Health Co | N/A | |
| Weimin MS | Medpace Holdings | N/A | |
| Kevin Yankton | Twist Bioscience Corp | 57 | |
| Paul Changelian | Aclaris Therapeutics | N/A | |
| Marcel Konrad | Caredx Inc | 48 | |
| Darya Chudova | Guardant Health | 50 | |
| Sri Kalluri | EXACT Sciences | N/A | |
| Erin Smith | Twist Bioscience Corp | N/A | |
| Michael Bell | Guardant Health | 55 | |
| Daniel OLeary | Medpace Holdings | N/A | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0535 |
Myriad Genetics Leadership Team
Elected by the shareholders, the Myriad Genetics' board of directors comprises two types of representatives: Myriad Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myriad. The board's role is to monitor Myriad Genetics' management team and ensure that shareholders' interests are well served. Myriad Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myriad Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Justin Hunter, Interim Secretary | ||
| Nicole Lambert, Chief Officer | ||
| Bryan Riggsbee, CFO, Executive VP and Treasurer | ||
| Jennifer Fox, Chief Officer | ||
| Clivetty Martinez, Chief Officer | ||
| Paul JD, President CEO | ||
| Paul Diaz, President CEO | ||
| Pamela Wong, Chief Officer | ||
| Shereen Solaiman, Chief Officer | ||
| Mark Verratti, President-President Assurex Health | ||
| Samraat Raha, Chief Officer | ||
| Natalie Munk, Principal Officer | ||
| Scott Leffler, Chief Officer | ||
| Scott Gleason, IR Contact Officer | ||
| Dale Muzzey, Chief Officer | ||
| Kevin Haas, Chief Officer | ||
| Matthew Scalo, Senior Relations | ||
| Glenn Farrell, Senior Officer |
Myriad Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myriad Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0535 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 1.45 B | ||||
| Shares Outstanding | 91.04 M | ||||
| Shares Owned By Insiders | 2.01 % | ||||
| Shares Owned By Institutions | 97.99 % | ||||
| Number Of Shares Shorted | 4.48 M | ||||
| Price To Earning | 31.95 X |
Pair Trading with Myriad Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.Moving together with Myriad Stock
| 0.65 | A | Agilent Technologies | PairCorr |
| 0.91 | ME | 23Andme Holding | PairCorr |
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Myriad Stock
| 0.75 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.47 | KZR | Kezar Life Sciences | PairCorr |
| 0.45 | RNXT | RenovoRx | PairCorr |
| 0.39 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.